The Study On The Efficacy And Safety Of Nedaplatin Combined With Docetaxel In The Treatment Of Advanced Esophageal Cancer

ObjectiveTo systematically evaluate the efficacy and safety of nedaplatin combined with docetaxel in the treatment of advanced esophageal cancer. MethodsComprehensive search of Pubmed, Embase, Cochrane Library, CNKI, CBM and VIP was conducted through December 2015 to identify eligible studies that met the inclusion criteria. Google Scholar was also used as a complementary source. Bibliography of retrieved articles was also screened manually. Two personnel independently extracted necessary data. Meta-analysis was conducted using fixed-or random-model to evaluate efficacy and safety of the regimen with Rev Man software. ResultsNine RCTs involving 601 patients(301 in the experimental group, 300 in the controlled group) were included in the Meta-analysis. Results showed that ND group, compared with PF group, had significant difference of outcomes on response rate [ RR=1.46, 95%CI(1.18, 1.81), P=0.0005].;the 1-year OS had significant difference [ RR=1.19, 95%CI(1.03, 1.38), P=0.02]. On the other hand, the experimental group was superior to the controlled group on toxicity with regard to gastrointestinal reactions, the pooled RR was [RR=0.46,95%CI(0.36,0.60),P<0.00001]. But the bone-marrow suppression was inferior [RR=1.43, 95%CI(1.12, 1.83), P=0.004]. ConclusionNedaplatin plus docetaxel are effective and safe in the treatment of advanced esophageal cancer, but, in comparison to cisplatin plus 5-fluorouracil, the superiority is not overwhelming. Due to the low quality and small sample size of this meta-analysis further well-designed study is warranted to confirm our findings.ObjectiveTo retrospectively evaluate the efficacy and safety of nedaplatin combined with docetaxel in the treatment of advanced esophageal cancer. MethodsCollected the clinical records and follow-up data of patients with advanced esophageal cancer from two cancer hospitals in Guangzhou. Patients received intravenously 60mg/m2 docetaxel for 1h, followed by 80mg/m2 nedaplatin for 2h, on day 1 every 28 days. Cycles continued until documented disease progression, unacceptable toxicity or patient's refusal. Retrospective evaluation on the response, survival time and toxicity was conducted. Univariate and multivariate analysis of several factors on survival were also performed. ResultsBetween 2008 and 2013, 368 patients were enrolled into the study. 26 patients achieved CR, 170 patients PR. The media PFS and OS were 4.4 months and 9 months, respectively. The non-hematological toxicities were generally mild to moderate; severe hematological toxicities included neutropenia and anemia, which observed in 85(23.1%) patients and 112(30.4%) patients; thrombocytopenia was mild(mostly Grade1); there were no febrile neutropenia and treatment-related death. ConclusionNedaplatin plus docetaxel is an effective and safe chemotherapy which is in particular suitable for the second-line treatment of advanced esophageal cancer. However, further perspective study is needed to consolidate our conclusion.